中文摘要：新候选抗生素的减少和抗生素耐药性的增加，需要开发替代抗菌素。噬菌体编码的内溶素（细胞裂解酶）是一类肽聚糖水解酶，可填补这一抗菌空白。在过去20年里，内溶素的发现、结构/功能、工程、免疫原性、毒性/安全性以及对动物模型的有效性等方面的研究得到了极大的发展。这些努力已使至少三种不同的内溶素进入到人体临床试验，用来对抗葡萄球菌。可以预见，以链球菌为靶标的内溶素可能是下一个转化发展方向。值得注意的是，链球菌疾病主要表现在可触及的粘膜上，这对蛋白质疗法有益。此外，在人类和动物中，许多已确认的链球菌疾病与单一物种有关，将进一步有利于靶向内溶素治疗。
外文摘要：The decline in new antibiotic candidates combined with an increase in antibiotic-resistance necessitates development of alternative antimicrobials. Bacteriophage-encoded endolysins (lysins) are a class of peptidoglycan hydrolases that have been proposed to fill this antimicrobial void. The past 20 years has seen a dramatic expansion of studies on endolysin discovery, structure/function, engineering, immunogenicity, toxicity/safety, and efficacy in animal models. These collective efforts have led to current human clinical trials on at least three different endolysins that are antimicrobial toward staphylococcal species. It can be anticipated that endolysins targeting streptococcal species may be next in line for translational development. Notably, streptococcal diseases largely manifest at accessible mucous membranes, which should be beneficial for protein therapeutics. Additionally, there are a number of well-identified streptococcal diseases in both humans and animals that are associated with a single species, further favoring a targeted endolysin therapeutic.
外文关键词：LYTIC ENZYME CPL-1；PHAGE LYSIN；MOUSE MODEL；ANTIBACTERIAL ACTIVITY；BACTERICIDAL ACTIVITY；ACTIVITY PROTECTS；IN-VITRO；MICE; PNEUMONIAE；ENDOPEPTIDASE
作者：Linden, SB；Alreja, AB；Nelson, DC
作者单位：Univ Maryland
期刊名称：CURRENT OPINION IN BIOTECHNOLOGY
期刊影响因子：8.288
出版年份：2021
出版刊次：SI
点击下载：噬菌体源性内溶素在抗链球菌病中的应用：现状与展望